Company Filing History:
Years Active: 2023
Title: John M S Bartlett: Innovator in Breast Cancer Prognosis
Introduction
John M S Bartlett is a notable inventor based in Toronto, Canada. He has made significant contributions to the field of cancer research, particularly in the area of breast cancer prognosis. His innovative work focuses on improving treatment outcomes for patients undergoing endocrine therapy.
Latest Patents
John M S Bartlett holds a patent titled "Gene signature of residual risk following endocrine treatment in early breast cancer." This patent describes a method for prognosing endocrine-only treatment in subjects with breast cancer. The method involves providing a tumor sample, determining the expression level of at least 40 specific genes, comparing these levels to reference expression levels from control samples, and ultimately assessing the residual risk associated with the breast cancer. This innovative approach aims to enhance the accuracy of prognostic assessments in breast cancer patients.
Career Highlights
John M S Bartlett is affiliated with the Ontario Institute for Cancer Research (OICR), where he conducts his research. His work has been instrumental in advancing the understanding of breast cancer treatment and prognosis. With 1 patent to his name, he continues to contribute to the scientific community through his research and innovations.
Collaborations
Some of his notable coworkers include Jane Bayani and Cindy Q Yao, who collaborate with him on various research projects. Their combined expertise enhances the research efforts at the Ontario Institute for Cancer Research.
Conclusion
John M S Bartlett is a pioneering inventor whose work in breast cancer prognosis is making a significant impact in the field of oncology. His innovative methods and dedication to research are paving the way for improved treatment strategies for patients.